KOSDAQBiotech & Pharma323990

Vaxcell-Bio Therapeutics

₩3,650▼ 0.95%2026-11-18 close
Market Cap
₩84.9B
Turnover
₩500M
Volume
140K
Shares out.
23.3M
PER
—
PBR
1.8×
EPS
-₩678
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Revenue Rising, Losses Persist at Vaxcell-Bio

Vaxcell-Bio's revenue rose for two consecutive quarters through the third quarter of 2026, yet operating losses have continued for five straight quarters, and most of its sales still come from pharmaceutical distribution.

  1. 1

    On a disclosed basis, revenue rose to KRW 1.9 billion in 2024 and KRW 7.06 billion in 2025, and the company attributes the growth mainly to its distribution business.

  2. 2

    Third-quarter 2026 revenue was KRW 2.04 billion, up 25.7% from the prior quarter, while the operating loss of KRW 3.73 billion remained in the red.

  3. 3

    The company has posted operating losses for four consecutive years through 2025, with the 2025 operating loss disclosed at KRW 15.5 billion.

  4. 4

    Distribution accounted for 98.5% of first-half 2026 sales, and the human cancer immunotherapy products still have no revenue.

  5. 5

    Cash and short-term financial instruments stood at KRW 14.8 billion at the end of June 2026, down 47.3% from a year earlier.

02

Business structure

Vaxcell-Bio develops anticancer immune cell therapies built on natural killer (NK) cells, dendritic cells (DC), and CAR-T and interleukin-based approaches. Its current sales structure, however, sits far from its pipeline.

Distribution sales in the first half of 2026 were KRW 3.1 billion, down 13.3% year on year, and accounted for 98.5% of total sales. The company cites growth in its distribution business as the main driver of 2025 revenue growth.

After acquiring a pharmaceutical distributor, annual sales cleared KRW 3 billion, the threshold tied to the KOSDAQ management-issue designation, although distribution operating profit fell sharply in the first half.

The human cancer immunotherapy products still generate no revenue, and the drug development segment's small sales come from veterinary products such as Boxlukin-15 and a companion-animal immune supplement. The drug development segment's first-half operating loss widened from KRW 8.8 billion to KRW 9.7 billion.

The lead pipeline is Vax-NK (VCB-1102), an NK cell therapy for advanced hepatocellular carcinoma, which has completed Phase 2a and is being pursued for conditional approval. Cell therapy production runs through a GMP facility in Hwasun with a floor area of 1,452 square meters. Compared with ABL Bio, which centers on its ALiTE bispecific platform, Vaxcell-Bio focuses on cell therapy.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩1.7B-₩3.4B−208.1%
2025Q4₩1.7B-₩3.6B−214.9%
2026Q1₩1.5B-₩4.6B−301.2%
2026Q2₩1.6B-₩5B−309.3%
2026Q3₩2B-₩3.7B−182.6%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022—-₩8.2B-₩6.8B—−29.3%3.6%
2023₩13,723,327-₩11.5B-₩10.3B−83851.2%−12.3%1.8%
2024₩1.9B-₩15B-₩10.6B−791.9%−14.8%6.9%
2025₩7.1B-₩15.5B-₩13.3B−219.6%−21.8%9.4%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On a disclosed basis, revenue grew from KRW 13.72 million in 2023 to KRW 1.9 billion in 2024, an increase of 13,737.3%, and then to KRW 7.06 billion in 2025, up 271.6%, marking two consecutive years of growth from 2024 through 2025. The company attributes the increase mainly to its distribution business.

Over the same period, operating losses were KRW 8.21 billion in 2022, KRW 11.5 billion in 2023, KRW 15 billion in 2024, and KRW 15.5 billion in 2025, a four-year run of losses in which the loss grew each year.

The 2025 net loss attributable to controlling shareholders was KRW 13.3 billion, and the consolidated net loss was also KRW 13.3 billion.

The operating margin improved from -791.9% in 2024 to -219.6% in 2025, but that reflects higher sales rather than a smaller loss, since the operating loss itself widened to KRW 15.5 billion. Operating cash flow was -KRW 10.6 billion in 2025.

On a quarterly basis, first-quarter 2026 revenue of KRW 1.54 billion, down 9.5% from the prior quarter, was the low point, followed by KRW 1.62 billion in the second quarter and KRW 2.04 billion in the third quarter, two consecutive quarters of growth. Third-quarter revenue rose 23.4% year on year.

The operating loss went from KRW 3.44 billion in the third quarter of 2025 to KRW 3.65 billion, KRW 4.62 billion, and KRW 5.02 billion through the second quarter of 2026, then narrowed to KRW 3.73 billion in the third quarter, which was still wider than a year earlier.

The net loss attributable to controlling shareholders over the last four quarters totaled KRW 15.8 billion. A review of the first-half 2026 semiannual report showed the operating loss widening from KRW 8.4 billion to KRW 9.6 billion.

In 2025, KRW 1 billion of the KRW 2.4 billion goodwill tied to the distributor acquisition was impaired, a one-time charge.

05

Industry analysis

South Korea's cell therapy sector is moving through a phased licensing process for cell processing facilities after the Advanced Regenerative Bio Act took effect. Vaxcell-Bio says it is expanding its licensed scope in sequence, from NK cell therapy to CAR cell therapy and autologous bone marrow-derived cells.

This is a regulatory shift shared across the sector. Cell therapies, however, typically require long clinical stages and have few approval precedents, so the path to commercialization is long. In terms of competitive position, Vaxcell-Bio focuses on cell therapy.

ABL Bio, in the same industry, has strengths in its ALiTE bispecific antibody platform and drug delivery systems, so its technology axis differs. Vaxcell-Bio has built expertise in NK cell and CAR cell therapies.

Observers have, however, pointed out that most pipeline assets other than Vax-NK remain at clinical or early research stages, raising concern about the next growth engine. Some have also argued that results in human medicines need to be secured.

Its veterinary immunotherapy approval follows a separate regulatory path from human therapeutics. Data on sector-wide demand, pricing, or cycle position were not confirmed, so this section is limited to qualitative description.

06

Outlook

The company's central tasks are pursuing conditional approval for Vax-NK and converting pipeline progress into human product revenue. Vaxcell-Bio has completed the Phase 2a trial of Vax-NK for hepatocellular carcinoma and is pursuing conditional approval.

Its small-cell lung cancer clinical study has submitted a results report, and a pancreatic cancer study is ongoing. The company is also broadening its pipeline into next-generation cell therapies such as CAR-MIL and CAR-T.

A November 2026 news report carried a headline stating that the company's CAR-T therapy achieved a complete response in solid tumors. On production, the company says it is expanding capacity through construction of a new headquarters building.

On partnering, it has signed agreements on AI-based cell and gene therapies and anticancer immunotherapy development and has explored out-licensing of bispecific and drug delivery technologies, but these agreements have not yet produced meaningful licensing fees or product sales.

On finances, cash and short-term instruments stood at KRW 14.8 billion at the end of June 2026, first-half operating cash outflow was KRW 6.6 billion, and the equity balance is KRW 61.1 billion against total liabilities of KRW 5.77 billion, giving a debt ratio of 9.4%.

The next checkpoints are the operating cash flow and the distribution segment's operating margin in the next annual report.

07

Valuation

PER
—
PBR
1.8×
ROE
-27.5%
EPS
-₩678
BPS
₩2,151
Dividend per share
₩0

Because the company has posted net losses over the last four quarters, its price-to-earnings ratio cannot be calculated. The price-to-book ratio is above 1x, so market capitalization trades at a premium to the KRW 61.1 billion of equity.

Equity attributable to controlling shareholders matches total equity at KRW 61.1 billion, so no non-controlling interest adjustment applies. The company does not pay dividends, which leaves its dividend yield at zero and not comparable with dividend-paying peers.

Because losses widened each year through 2025, the valuation is closely tied to when earnings recover. The 2025 operating loss of KRW 15.5 billion and the first-half 2026 operating loss of KRW 9.6 billion are of similar scale on an annual basis.

A share price above book value means the market is valuing business prospects beyond the balance sheet assets. The basis for that valuation depends on whether Vax-NK is approved and when human product revenue appears.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Expanding sales base

Revenue reached KRW 7.06 billion in 2025, up 271.6%, and third-quarter 2026 revenue rose for a second consecutive quarter to KRW 2.04 billion. The distributor acquisition lifted annual sales above KRW 3 billion, the threshold tied to the management-issue designation. The third-quarter 2026 operating loss narrowed from the prior quarter.

Clinical pipeline progress

The Vax-NK liver cancer Phase 2a trial has been completed, and the company is pursuing conditional approval on that basis. A small-cell lung cancer clinical study has submitted its results report, and a pancreatic cancer study continues. The company is broadening its pipeline into CAR-MIL and CAR-T therapies.

Low debt burden

Total equity at the end of 2025 was KRW 61.1 billion against total liabilities of KRW 5.77 billion. The debt ratio rose from 3.6% in 2022 to 9.4% in 2025 but remains low. Equity attributable to controlling shareholders accounts for all of total equity, which keeps the capital structure simple.

09

Bear factors

Persistent losses that widened

Operating losses ran for four consecutive years, from KRW 8.21 billion in 2022 to KRW 15.5 billion in 2025, with the loss larger each year. The net loss attributable to controlling shareholders over the last four quarters totaled KRW 15.8 billion.

Reliance on distribution and no core product sales

First-half 2026 distribution sales were KRW 3.1 billion, down 13.3% year on year, and made up 98.5% of total sales. Distribution operating profit fell 66.8% from KRW 400 million to KRW 100 million.

The human cancer immunotherapy products still generate no revenue, and the drug development segment's operating loss widened to KRW 9.7 billion.

Cash decline and goodwill impairment

Operations consumed KRW 6.6 billion of cash in the first half. Of the KRW 2.4 billion goodwill recognized in the distributor acquisition, KRW 1 billion was impaired in 2025.

10

Risk factors

Funding risk

Operating cash outflows persisted each year from 2022 through 2025, reaching -KRW 10.6 billion in 2025. Cash and short-term instruments fell to KRW 14.8 billion by the end of June 2026. If losses continue, additional funding could change the capital structure.

Approval and clinical risk

Vax-NK has completed Phase 2a but has not received marketing approval for human use. The company's current marketing approval covers only an animal immunotherapy product. Most other pipeline assets remain at clinical or early research stages, so development timelines may shift with the results.

Distribution profitability and goodwill

The cost ratio in the distribution business, which accounts for most sales, rose from 83.2% to 93.2% in the first half of 2026. Gross profit fell from KRW 600 million to KRW 200 million. The company has not disclosed the earnings forecasts and assumptions used in its goodwill impairment test.

11

What to watch next

  1. Around February 2027 (expected; schedule not confirmed)

    Fourth-quarter and full-year 2026 preliminary results. The checkpoints are whether the operating loss streak extends further and whether revenue growth continues after two consecutive quarters of increases.

  2. By March 31, 2027

    Filing of the 2026 annual report. The next regular filing will show full-year operating cash flow, the distribution segment's operating margin, and the drug development segment's loss.

  3. By May 15, 2027

    Filing of the first-quarter 2027 quarterly report. The checkpoint is whether cash and short-term instruments, KRW 14.8 billion at mid-2026, continue to decline.

  4. After November 2026 (timing undetermined)

    The outcome of the Vax-NK conditional approval effort and whether human product revenue begins. Pipeline assessment will depend on the approval progress.

12

Overall view

Vaxcell-Bio's third-quarter 2026 revenue of KRW 2.04 billion rose for a second consecutive quarter, and its operating loss narrowed from the prior quarter.

Still, operating losses ran for four consecutive years through 2025, and the net loss attributable to controlling shareholders over the last four quarters totaled KRW 15.8 billion. Distribution accounts for 98.5% of sales, and the human cancer immunotherapy products still have no revenue.

Bullish factors include completion of the Vax-NK Phase 2a trial, the pursuit of conditional approval, and a low debt ratio of 9.4% against KRW 61.1 billion of equity. Bearish factors include widening losses, cash falling to KRW 14.8 billion, a rising distribution cost ratio, and goodwill impairment.

The valuation rests on a price-to-book ratio above 1x with no meaningful earnings multiple, and its interpretation depends on when earnings recover and whether Vax-NK is approved. The next checkpoints are operating cash flow and the distribution segment's operating margin in the 2026 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.fnguide.com
  2. comp.wisereport.co.kr
  3. alphasquare.co.kr
  4. biz.newdaily.co.kr
  5. jobkorea.co.kr
  6. newspim.com
  7. news.nate.com
  8. news.nate.com
  9. m.news.nate.com
  10. m.irgo.co.kr
  11. saramin.co.kr
  12. m.saramin.co.kr
  13. m.medigatenews.com
  14. econovill.com
  15. biotimes.co.kr
  16. sisajournal-e.com
  17. biotimes.co.kr
  18. biospectator.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis